Long non‐coding RNA ADAMTS9‐AS1 suppresses colorectal cancer by inhibiting the Wnt/β‐catenin signalling pathway and is a potential diagnostic biomarker

Li, Ning; Li, Juan; Mi, Qi; Xie, Yan; Li, Peilong; Wang, Lili; Binang, Helen Barong; Wang, Qing; Wang, Yanlei; Chen, Yingjie; Wang, Yunshan; Mao, Hongzhi; Li, Du; Wang, Chuanxin

doi:10.1111/jcmm.15713

Cited by 45 publications

(33 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the lncRNAs in the frlncRNA signature, several have been demonstrated to be related to immunity, ferroptosis, and malignancy. For instance, ADAMTS9-AS1, which was reported to suppress the malignant phenotypes of breast cancer cells [ 32 ], could also regulate colorectal cancer cell proliferation and migration [ 33 ]. The gene-pair strategy also helped disclose the underlying association between the paired lncRNAs.…”

Section: Discussionmentioning

confidence: 99%

Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

The tight relationship between ferroptotic cell death and immune response demonstrated by recent studies enlightened us to detect the underlying roles of ferroptosis-related long noncoding RNAs (frlncRNAs) in the tumor microenvironment of bladder cancer (BCa). We collected 121 ferroptosis regulators from previous studies. Based on their expression values, 408 cases with BCa were clustered. The patients in different clusters showed diverse immune infiltration, immunotherapy response, and chemotherapy effectiveness, revalidating the tight correlation with ferroptosis and tumor immunity. Through differential, coexpression, Kaplan-Meier, Lasso, and Cox analysis, we developed a 22-lncRNA-pair signature to predict the prognosis of BCa based on gene-pair strategy, where there is no need for definite expression values. The areas under the curves are all over 0.8. The risk model also helped to predict immune infiltration, immunotherapeutic outcomes, and chemotherapy sensitivity. Totally, the prognostic assessment model indicated a promising predictive value, also providing clues for the interaction between ferroptosis and BCa immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tumor cells proliferation and invasion are important aggressive behavior of human cancers. 13 , 14 A large number of studies have revealed that lncRNA can function as promoter or inhibitor of human cancer proliferation, invasion and it was widely acknowledged that numerous lncRNAs were involved in the progression of CRC. 2 For example, FOXCUT (a novel long noncoding RNA) promotes the colorectal cancer proliferation and invasion through activating FOXC1/PI3K/AKT pathway.…”

Section: Discussionmentioning

confidence: 99%

LINC01224 Promotes Colorectal Cancer Progression by Sponging miR-2467

Chen

Zhao

et al. 2021

CMAR

View full text Add to dashboard Cite

Introduction Colorectal cancer (CRC) is one of the most common human cancers and a leading cause of cancer-related death. Accumulating evidence has confirmed that long non-coding RNA (lncRNA) plays crucial roles in CRC development. Methods qRT-PCR was performed to examine the expressions of LINC01224 and miR-2467. CCK-8 assay, colony formation assay and transwell invasion assay were used to examine the progression of breast cancer cells. Luciferase and RNA-binding protein immunoprecipitation (RIP) assay were applied to verify the binding site. Correlation analysis of miR-2467 and LINC01224 expression in lung cancer tissues was shown. Pancreatic cancer cells growth in vivo was evaluated using xenograft tumor assay. Results LINC01224 expression was observed to be up-regulated in CRC tissues and cell lines. Functional studies suggested that LINC01224 silence inhibited CRC cells proliferation and invasion of CRC cells, while co-transfection with a miR-2467 inhibitor reversed these biological effects. Luciferase reporter assays illustrated that LINC01224 regulated miR-2467 directly, and RNA-binding protein immunoprecipitation (RIP) further confirmed that the suppression of LINC01224 by miR-2467 was in an RISC-dependent manner. Finally, LINC01224 silence inhibited the growth CRC cells in vivo. Conclusion In conclusion, our findings showed that LINC01224 promoted CRC progression through sponging miR-2467. LINC01224 may serve as a potential diagnostic biomarker and therapeutic target for CRC patients.

show abstract

“…Its sense transcript, ADAMTS9 (ADAM metallopeptidase with thrombospondin type 1 motif 9), encodes for a disintegrin and metalloproteinase with thrombospondin motifs enzyme; single nucleotide polymorphisms in ADAMTS9 sequence have been associated with cognitive aging [49]. ADAMTS9 suppresses β-catenin and the canonical Wnt signaling pathway [50] that is known to be inhibited in the AD brain [51,52].…”

Section: Discussionmentioning

confidence: 99%

Uncharacterized RNAs in Plasma of Alzheimer’s Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

Barbagallo

Martino

Grasso

et al. 2020

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) diagnosis is actually based on clinical evaluation and brain-imaging tests, and it can often be confirmed only post-mortem. Therefore, new non-invasive molecular biomarkers are necessary to improve AD diagnosis. As circulating microRNA biomarkers have been proposed for many diseases, including AD, we aimed to identify new diagnostic non-small RNAs in AD. Whole transcriptome analysis was performed on plasma samples of five AD and five unaffected individuals (CTRL) using the Clariom D Pico Assay, followed by validation in real-time PCR on 37 AD patients and 37 CTRL. Six differentially expressed (DE) transcripts were identified: GS1-304P7.3 (upregulated), NONHSAT090268, TC0100011037, TC0400008478, TC1400008125, and UBE2V1 (downregulated). Peripheral blood mononuclear cells (PBMCs) may influence the expression of circulating RNAs and their analysis has been proposed to improve AD clinical management. Accordingly, DE transcript expression was also evaluated in PBMCs, showing no difference between AD and CTRL. ROC (receiver operating characteristic) curve analysis was performed to evaluate the diagnostic accuracy of each DE transcript and a signature including all of them. A correlation between cognitive impairment and GS1-304P7.3, NONHSAT090268, TC0100011037, and TC0400008478 was detected, suggesting a potential association between their extracellular abundance and AD clinical phenotype. Finally, this study identified six transcripts showing altered expression in the plasma of AD patients. Given the need for new, accurate blood biomarkers for AD diagnosis, these transcripts may be considered for further analyses in larger cohorts, also in combination with other biomarkers, aiming to identify specific RNA-based biomarkers to be eventually applied to clinical practice.

show abstract

Long non‐coding RNA ADAMTS9‐AS1 suppresses colorectal cancer by inhibiting the Wnt/β‐catenin signalling pathway and is a potential diagnostic biomarker

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 45 publications

References 51 publications

Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer

Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer

LINC01224 Promotes Colorectal Cancer Progression by Sponging miR-2467

Uncharacterized RNAs in Plasma of Alzheimer’s Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

Contact Info

Product

Resources

About